RAPT Therapeutics (RAPT)

• Market cap: $1.67B
• 1 day: -0.03%
• 5 days: -0.03%
• 1 month: 60.8%
• 3 months: 93.52%
• 6 months: 399.83%
• Year to date: 80.94%
• 1 year: 515.71%
• 5 years: -63.84%
• 10 years: -44.59%
• Sector: Healthcare
• Industry: Biotechnology

About: RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Employees: 60